SecBot SecBot

SNY drug pipeline

Sanofi · 22 rated drugs
$48.37
−0.2% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.3%
1-day, median of 11 events
IV rank
No data
No current options data
Rated drugs
22
1 bearish · 1 mixed · 20 neutral
Phase 3 trials
19
0 with results posted

Upcoming catalysts

4 dated
  1. Dec 1, 2026
    SP0289
    Phase 2 primary completion
  2. Dec 1, 2026
    PCV21
    Phase 3 primary completion
  3. Jan 15, 2027
    ALTUVIIIO
    Phase 3 primary completion
  4. Jan 18, 2027
    Investigational hMPV/RSV vaccine
    Phase 2 primary completion

Drugs

soonest catalyst first
◆ mixed
Impact
PhaseFiled/PDUFA for Gaucher type 3 (NDA under FDA priority review); Phase 3 ongoing in Fabry disease; Phase 3 GM2 (Tay-Sachs
Time to marketUS approval decision for Gaucher type 3 on November 25, 2026 (PDUFA); commercial launch could follow in late 2026/early 2027 if approved. The Fabry Phase 3 is still running (full completion estimated Dec 2027), so a Fabry filing is likely 2028 or later.

venglustat Updated Aug 2

What to watch

Watch the November 25, 2026 PDUFA decision for Gaucher disease type 3, a positive outcome (priority review plus a pivotal study that met both primary endpoints) would be a modest positive for SNY but not a needle-mover given Sanofi's size. More interesting for dedicated investors: whether topline data from the Phase 3 Fabry trial (NCT05280548, primary completion passed May 15, 2026) emerges before year-end, since Fabry is a larger market; the local data shows no results posted yet.

Bull case
  • NDA granted FDA PRIORITY REVIEW for Gaucher type 3 with target action date Nov 25, 2026, a dated, likely near-term approval decision (Sanofi 6-K, filed June 8, 2026, accession 000119312526260613).
  • Pivotal Phase 3 LEAP2MONO met BOTH primary endpoints and three of four key secondary endpoints, per the June 8, 2026 6-K analysis.
  • If approved, venglustat would be the first US treatment addressing neurological manifestations of GD3, an oral drug that can reach the brain, versus infusion enzyme-replacement therapies (per the same 6-K).
Bear case
  • Gaucher type 3 is an ultrarare disease, so even a successful launch is a small revenue contributor, and Sanofi is a ~$109-110B market-cap company, so this single drug is unlikely to drive meaningful SNY share-price movement.
  • Program track record is checkered: the Phase 3 GM2 gangliosidosis (Tay-Sachs/Sandhoff) trial (NCT04221451, n=75) is TERMINATED with results, showing development risk in this platform.
  • The Phase 3 Fabry trial (NCT05280548) passed its estimated primary completion (May 15, 2026) yet no results appear in local data, a readout that could disappoint and is a bigger commercial opportunity than GD3.
● neutral
Impact
PhaseApproved
Time to marketAlready on the market since August 2021 (US) for late-onset Pompe disease. Label expansion to infantile-onset Pompe could come in 2027 pending FDA submission and review.

Nexviazyme avalglucosidase alfa Updated Jul 7

What to watch

The Baby-COMET Phase 3 topline readout (June 30, 2026) was a positive milestone already priced in. Watch for the formal FDA submission in H2 2026 and the eventual PDUFA decision, likely a 2027 event, which could add ~€100-200M in peak sales from the infantile-onset population. The bigger competitive overhang is BioMarin's newly acquired Pombiliti+Opfolda combo, which Danish regulators found equally effective and which may pressure Sanofi's Pompe franchise pricing.

Bull case
  • Nexviazyme sales grew 17-26% YoY in 2025, reaching ~€790M annually, and the Pompe franchise (including Myozyme) hit €320M in Q1 2026 alone, showing strong commercial traction.
  • The Baby-COMET Phase 3 trial (June 30, 2026) was a clean win: met all primary and secondary endpoints in infantile-onset Pompe, with no serious adverse events reported. This unlocks a label-expansion opportunity into a new, underserved patient population.
  • Sanofi's Pompe franchise is deeply entrenched with treating physicians (two marketed ERTs) and has a head start on BioMarin/Amicus in commercial infrastructure.
Bear case
  • BioMarin completed its $4.8B acquisition of Amicus Therapeutics in April 2026, adding the Pombiliti+Opfolda combo, a direct competitor that a meta-analysis suggested may outperform Nexviazyme in ERT-experienced late-onset Pompe patients.
  • The Danish Medicines Council found Nexviazyme, Myozyme, and Pombiliti+Opfolda clinically equivalent, opening the door to competitive tendering and pricing pressure across European markets.
  • Nexviazyme partially cannibalizes Sanofi's own older ERT Myozyme/Lumizyme, the total Pompe franchise grew only 2.4% YoY in Q1 2026 (€320M), suggesting market share shifts rather than pure expansion.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available in the US (since March 2025), China (since Dec 2025), and India (since Oct 2026).

Qfitlia fitusiran Updated Oct 31

What to watch

Qfitlia is already approved in the US (March 2025), China (Dec 2025), and India (Oct 2026). The next catalysts to watch are potential European Medicines Agency (EMA) approval and additional country-level launches, though no hard dates are publicly set. Commercial adoption and payer uptake in the US will determine whether the drug reaches its projected $500M-$1.5B peak sales range, but for Sanofi this is a modest contributor within a $50B+ revenue base.

Bull case
  • Qfitlia is the first and only FDA-approved antithrombin-lowering therapy for hemophilia, offering a novel RNAi mechanism that works for both hemophilia A and B, with or without inhibitors, a broader label than most competitors.
  • Dosing is just once every two months (as few as 6 injections per year) via subcutaneous injection, a significant convenience advantage over older therapies requiring frequent IV infusions.
  • Phase 3 ATLAS trials demonstrated a 71-73% reduction in annualized bleeding rate versus on-demand therapy, and up to 90% reduction versus on-demand bypassing agents in inhibitor patients.
Bear case
  • Qfitlia carries an FDA boxed warning for thrombotic events and gallbladder disease, requiring mandatory antithrombin monitoring that may limit adoption versus competitors without such requirements.
  • The hemophilia market is increasingly crowded: Roche's Hemlibra (emicizumab) is the entrenched market leader, and Pfizer's Hympavzi and Novo Nordisk's Alhemo are competing for the same non-factor prophylaxis space.
  • At a ~$642,000/year list price, Qfitlia faces payer pushback and rebate pressure, and Sanofi expects actual net prices to be significantly lower after discounts.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2014.

Alprolix eftrenonacog alfa Updated Oct 30

What to watch

Alprolix has no upcoming binary catalysts (PDUFA dates or pivotal readouts) as an already-approved, marketed drug. The next event to watch is any Sanofi quarterly earnings disclosure of rare-blood-disorders segment revenue, which would show whether Alprolix is holding share against Idelvion and newer non-factor competitors. The key long-term overhang is the projected July 2028 loss of exclusivity, which could open the door to biosimilar competition.

Bull case
  • First-to-market extended half-life factor IX therapy with over 10 years of real-world data and established physician trust.
  • Room temperature storage stability (up to 6 months at ≤30°C) adds patient convenience and competitive differentiation.
  • Part of Sanofi's broader rare-blood-disorders franchise, benefiting from cross-selling and integrated patient support services.
Bear case
  • Faces direct competition from Idelvion (CSL Behring), another extended half-life factor IX product with 14-day dosing.
  • Gene therapy Hemgenix (CSL Behring) offers a one-time curative option for eligible adults, potentially shrinking the addressable patient pool.
  • Newer non-factor therapies (Sanofi's own Qfitlia, Pfizer's Hympavzi, Novo Nordisk's Alhemo) provide subcutaneous injection alternatives.
● neutral
Impact
PhaseApproved (US)
Time to marketAlready approved and marketed in the U.S. (first FDA approval Feb 22, 2023); sold commercially

ALTUVIIIO efanesoctocog alfa Updated Aug 1

What to watch

For SNY holders, ALTUVIIIO is a genuine growth product but not a stock-moving event: the approval binary passed in Feb 2023, and Sanofi's share-price catalysts live elsewhere (e.g., Dupixent momentum and a venglustat FDA decision reportedly targeted Nov 25, 2026). Watch quarterly Sanofi disclosures for ALTUVIIIO sales growth and the pending presentation of a completed Phase 3 joint-health study (NCT05817812, results not yet posted) as the main drug-specific updates.

Bull case
  • First-in-class 'high sustained' factor VIII: engineered to work independently of endogenous von Willebrand factor, with a reported 3-4x longer half-life than standard and extended half-life (EHL) FVIII products, enabling once-weekly dosing (Haematologica article).
  • Broad US label: approved for adults AND children with hemophilia A for routine prophylaxis, on-demand treatment/control of bleeding, and perioperative (surgery) management (FDA page; Sanofi press release).
  • Commercial momentum: ALTUVIIIO is named among Sanofi's product portfolio in H1 2026 results, in which Sanofi reported net sales of €22,106M (+11.1% reported, +15.7% CER) and raised FY2026 guidance, with 'new launches' a stated growth driver (SEC 6-K analysis, Jul 30, 2026).
Bear case
  • The defining binary already passed: US approval happened Feb 2023, and SecBot's local data shows no pending FDA decision or pivotal readout for ALTUVIIIO, so there is no scheduled event likely to move SNY shares on this drug alone.
  • Concentration risk is minimal but two-way: at a roughly $109B market cap, ALTUVIIIO is one of several 'new launch' contributors while Dupixent (€9,324M H1 2026, +34.4% CER) dominates, drug-specific news is diluted in the SNY story, which in H1 2026 was dominated by a €952M amlitelimab impairment and pipeline setbacks.
  • Competitive market: ALTUVIIIO's edge is defined against standard and EHL factor VIII products (Haematologica), and hemophilia A prophylaxis is a crowded, payer-sensitive category where rivals include subcutaneous and longer-acting alternatives; market-share and reimbursement outcomes are unproven over time.
● neutral
Impact
PhaseApproved in China (NMPA); Phase III ongoing for cGVHD
Time to marketAlready marketed in China. Timeline for US/EU regulatory filings is not yet disclosed; Sanofi is still in early-stage global development.

Anxu rovadicitinib Updated Oct 31

What to watch

Watch for Sanofi's progress advancing rovadicitinib into US/EU clinical trials and any Phase III cGVHD data readouts, which would be the next meaningful catalysts. The drug is already generating commercial revenue in China, but for Sanofi's stock, this is a minor contributor relative to Dupixent and other core franchises.

Bull case
  • First-in-class dual JAK/ROCK inhibitor with a differentiated mechanism that could address both inflammatory and fibrotic components of disease
  • Already approved and generating revenue in China, de-risking the mechanism
  • Strong Phase Ib/IIa cGVHD data published in Blood showing 59.1% response rate and steroid-sparing effect, supporting a large addressable market
Bear case
  • For Sanofi, a $53B market-cap company, this is a small pipeline addition with no near-term impact on the stock
  • No US or EU regulatory filing has occurred; global development timeline is uncertain and likely years away
  • The myelofibrosis market is competitive with approved JAK inhibitors like ruxolitinib, fedratinib, and pacritinib
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 1997. Widely available as a generic.

Aprovel irbesartan Updated Oct 31

What to watch

Aprovel/irbesartan has no scheduled PDUFA dates, pivotal readouts, or regulatory catalysts. Sanofi's stock is driven by its broader pipeline (Dupixent, vaccines, rare disease assets) and overall earnings, not this off-patent hypertension drug. Investors should watch Sanofi's pipeline programs and quarterly results rather than this mature product.

Bull case
  • Irbesartan remains a widely prescribed antihypertensive with steady demand, generating roughly $494 million in 2025 global sales for Sanofi, up 12.7% year-over-year.
  • The drug has a well-established safety profile and is included in major hypertension treatment guidelines, ensuring continued prescription volume.
  • Sanofi's broad portfolio means the drug contributes predictable, if modest, cash flow with no further R&D investment required.
Bear case
  • The drug is off-patent and faces extensive generic competition from multiple manufacturers (Macleods, Hisun, and others), which severely limits pricing power and margins.
  • At roughly $494 million in annual sales, irbesartan represents less than 1% of Sanofi's total revenue, making it immaterial to the company's investment thesis.
  • There are no upcoming catalysts for this drug that could move Sanofi's share price, as it is a mature product with no pending regulatory actions or new indications.
● neutral
Impact
PhaseApproved
Time to marketAlready on the market. First approved in the US in February 2019 and in the EU in September 2018.

Cablivi caplacizumab Updated Oct 30

What to watch

Cablivi has no scheduled PDUFA dates, AdComms, or pivotal readouts in the next 12 months. The key binary event (pediatric label expansion) already passed in early 2026. Watch Sanofi's Q4 2026 earnings (late January 2027) for Cablivi's quarterly sales trajectory and any commentary on competitive dynamics from emerging aTTP therapies. The next major Sanofi rare-disease catalyst is the venglustat PDUFA for Gaucher disease type 3 on November 25, 2026, a separate drug.

Bull case
  • Cablivi is the first and only FDA-approved therapy specifically for aTTP, giving it a strong niche position in a rare disease with high mortality if untreated.
  • Sales grew 9.7% in 2024 to EUR 249 million, with continued growth from increased diagnosis rates, expanded specialty hematology centers, and the new pediatric indication (12+).
  • The pediatric label expansion (December 2025) opens a new patient segment with no other approved targeted therapy, supporting continued revenue growth.
Bear case
  • Cablivi is a tiny fraction (roughly 0.5%) of Sanofi's total revenue, so even strong sales growth has negligible impact on the stock.
  • The aTTP market is very small (ultra-rare disease), capping the drug's peak revenue potential well below blockbuster status.
  • Emerging competitors such as rilzabrutinib, ianalumab, and mezagitamab could eventually challenge Cablivi's position in the TTP treatment landscape.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercialized since 1994. The latest label expansion (Type 3 Gaucher) was approved by the FDA in January 2026.

Cerezyme imiglucerase Updated Oct 30

What to watch

The next catalyst for Cerezyme was the FDA label expansion in January 2026, which has already occurred. No new PDUFA or pivotal readout is scheduled for this mature product. Watch for biosimilar competition (Abcertin completed Phase 1 in July 2025) and quarterly sales trends in Sanofi's rare disease reporting, but neither is a binary event for the stock.

Bull case
  • The FDA expanded Cerezyme's label in January 2026 to include non-CNS symptoms of Type 3 Gaucher disease and pediatric patients under 2 years old, making it the first and only FDA-approved therapy for Type 3 Gaucher, which could support patient growth.
  • Cerezyme has over 30 years of real-world use and is the #1 prescribed enzyme replacement therapy for Gaucher disease Type 1 in the U.S., giving it strong brand recognition and physician familiarity.
  • Sanofi's Q3 2026 results showed double-digit growth with rare disease medicines contributing to improved product mix, and the company raised its full-year guidance, reflecting overall business strength.
Bear case
  • Biosimilar competition is emerging: Abcertin, a biosimilar candidate for imiglucerase, met equivalence criteria in a Phase 1 study in July 2025, which could pressure Cerezyme's pricing and market share over time.
  • Cerezyme faces entrenched competition from other enzyme replacement therapies (Takeda's VPRIV, Pfizer's Elelyso) and oral substrate-reduction therapies (Cerdelga, Zavesca), limiting volume and pricing expansion.
  • Cerezyme sales were broadly stable at EUR 171 million in FY2025 (+2.9%), with price partly offsetting patient growth, indicating a mature product with limited growth trajectory.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2003.

Fabrazyme agalsidase beta Updated Oct 30

What to watch

Fabrazyme has no upcoming PDUFA date, pivotal readout, or label-expansion decision in the next 12 months. Watch for resolution of the FDA Warning Letter at the Waterford plant (which could affect supply continuity) and for biosimilar entry in major markets. Neither is a hard binary catalyst for Sanofi's stock given the drug's small revenue contribution.

Bull case
  • Fabrazyme remains the #1 prescribed FDA-approved treatment for Fabry disease, with over 20 years of real-world data supporting its safety and efficacy across all ages (2+), genders, and disease severities.
  • The EMA has listed the Fabrazyme supply shortage as resolved, suggesting manufacturing disruptions may be stabilizing.
  • Sanofi's total revenue reached EUR 43.6 billion in 2025 with 9.9% growth, and the broader rare-disease portfolio provides diversification against any single product issue.
Bear case
  • The FDA issued a Warning Letter (June 22, 2026) to Sanofi's Genzyme Ireland Waterford facility citing data integrity violations and CGMP failures, which led to supply disruptions for Fabrazyme and could lead to further regulatory action or remediation costs.
  • Biosimilar competition is emerging: Laboratorio Biosidus launched Agalzyme (agalsidase beta biosimilar) in Argentina and Latin America in 2025, and other biosimilars (GNR-062, AGABIO) are in development, potentially eroding Fabrazyme's market share over time.
  • Fabrazyme generated only ~EUR 252 million in 2025 (roughly 0.6% of Sanofi's total revenue), making it a minor product that could face margin pressure from biosimilars without meaningfully impacting Sanofi's overall financials in either direction.
● neutral
Impact
PhaseApproved / marketed (comparator in a completed Phase 3 trial; next-gen flu programs in Phase 2)
Time to marketAlready on the market (long-approved seasonal flu vaccine; reformulated annually for new strains)

Fluzone influenza vaccine (inactivated) Updated Aug 2

What to watch

If you want flu-vaccine upside, watch Sanofi's separate next-gen flu programs (Phase 2 mRNA/combination trials NCT06744205, NCT06695117 with results pending), which are different molecules from Fluzone.

Bull case
  • Established standard of care: 'Fluzone High Dose' appears as the active comparator in a completed, ~9,320-patient Phase 3 Novavax COVID+flu combination trial (NCT06291857), evidence it is a recognized benchmark flu vaccine.
  • Sanofi is an active, filing, financially healthy developer, multiple SEC 6-Ks filed in the last 90 days (e.g., 2026-07-30, 2026-07-27), and the ADR trades at $43.08 with an analyst mean price target of $54.61 and 16 Buy/Strong Buy ratings vs 1 Sell.
  • Sanofi's broader flu franchise is being modernized: Phase 2 next-gen flu/combination trials (NCT06744205 hexavalent mRNA flu, NCT06695117 IIV-HD + COVID combo, NCT06695130) recently completed with results pending, showing ongoing investment around the franchise.
Bear case
  • No hard dated catalyst: the SecBot FDA cache shows zero action rows for 'Fluzone' or 'influenza' in the past 365 days, and no upcoming FDA catalysts/events for SNY in the next 30 days, annual strain swaps are routine, not binary events.
  • Concentration is tiny: Fluzone is one seasonal vaccine among many products at a mega-cap ($43.08 ADR, 52-week range $40.89-$52.68); even a good or bad flu season moves Sanofi's stock modestly.
  • Institutional sentiment in the local 13F data was mixed-to-negative for Q2 2026: tracked managers showed trims (ASSETMARK -58.6%, Atria -27.7%, Farther Finance -36.2%) and a near-exit (Private Advisor Group -91.9%) against two doubles, and there were small SEC fails-to-deliver events (~$1.2M-$1.9M) in June-July 2026.
▼ bearish
Impact
PhaseApproved
Time to marketAlready on market since April 2000 (26+ years).

Lantus insulin glargine Updated Oct 31

What to watch

Lantus has no upcoming FDA catalyst; the next event to watch is the finalization of the October 2026 tentative antitrust settlement with US wholesalers, which could involve a cash payment. More broadly, watch Sanofi's quarterly earnings for continued erosion of Lantus revenue as biosimilars (Semglee, LANGLARA) gain pharmacy shelf share. The real value story at Sanofi has shifted to Dupixent and newer launches, not Lantus.

Bull case
  • Lantus still generated roughly EUR 1.7 billion in 2025 revenue, making it a meaningful cash-flow contributor even in decline.
  • Supply shortages of Lantus SoloStar pens in mid-2026 suggest persistent demand, and some patients may switch back once supply normalizes.
  • Sanofi's diversified portfolio means Lantus's decline is manageable; Q3 2026 total company sales grew 14.3% at CER, driven by Dupixent and new launches, offsetting the Lantus erosion.
Bear case
  • Biosimilar erosion is accelerating: Semglee (Mylan) was the first interchangeable biosimilar insulin approved in 2021, and LANGLARA (Lannett/Lanexa/Sunshine Lake) was approved as an interchangeable biosimilar in May 2026, directly substitutable at the pharmacy counter without prescriber intervention.
  • Lantus revenue fell to approximately EUR 1.7 billion in 2025 (Statista), a fraction of its peak, and analysts describe a 'Lantus cliff' as biosimilar adoption grows.
  • Sanofi reached a tentative antitrust settlement on October 28, 2026 to resolve wholesaler claims that it used improper patent listings to suppress Lantus competition, which could involve financial penalties or business practice changes.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 1993. Ex-US commercial rights being transferred to Cheplapharm expected Q1 2027.

Lovenox enoxaparin sodium Updated Oct 31

What to watch

Lovenox has no upcoming binary catalysts. The key event to watch is the closing of the Cheplapharm partnership (expected Q1 2027), which transfers ex-US Lovenox rights in exchange for a 26.4% stake in Cheplapharm. This is a portfolio cleanup, not a value-creating catalyst for Sanofi shares. For Sanofi investors, the focus should remain on growth drivers like Dupixent and the pipeline, not this declining legacy asset.

Bull case
  • Lovenox remains a clinically important hospital anticoagulant with entrenched usage in DVT prophylaxis and ACS, generating EUR 174M in Q3 2026 alone.
  • The Cheplapharm partnership (26.4% equity stake) lets Sanofi retain upside from the mature medicines portfolio while offloading manufacturing and commercial costs.
  • Sanofi's Q3 2026 earnings beat estimates and the company raised full-year guidance, showing the overall business is strong even as legacy assets like Lovenox decline.
Bear case
  • Lovenox is a mature, off-patent drug facing extensive generic and biosimilar competition in both the US and Europe, driving persistent revenue declines (Q3 2026 sales down 12.8% YoY to EUR 174M).
  • Sanofi is actively divesting the asset: the September 2026 Cheplapharm deal transfers ex-US Lovenox rights, signaling the drug is no longer core to Sanofi's innovation-focused strategy.
  • Oral anticoagulants (e.g., apixaban/Eliquis, rivaroxaban/Xarelto) continue to erode the injectable LMWH market, structurally pressuring Lovenox's long-term relevance.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2006.

Myozyme alglucosidase alfa Updated Oct 30

What to watch

Myozyme is a declining legacy asset being actively replaced by Sanofi's own next-gen Pompe drug Nexviazyme. The key near-term event to watch is whether Sanofi resolves the Waterford manufacturing issues (FDA warning letter from June 2026) that caused supply shortages in August 2026, and whether Nexviazyme wins FDA approval for infantile-onset Pompe (submission planned for H2 2026), which would further accelerate the switch away from Myozyme.

Bull case
  • Myozyme/Lumizyme remains the only FDA-approved enzyme replacement therapy for certain Pompe disease patient populations and continues to generate meaningful revenue (EUR 105 million in Q3 2026 alone), with no generic or biosimilar competition on the market.
  • The drug has a long-established safety and efficacy profile with over 20 years of real-world use. Sanofi's Genzyme division maintains a dominant position in Pompe disease treatment, with Myozyme and Nexviazyme together capturing the entire ERT market.
  • Sanofi's Q3 2026 earnings beat estimates and the company raised full-year guidance, demonstrating that the rare disease franchise (including Myozyme) remains profitable despite the ongoing transition to Nexviazyme.
Bear case
  • Myozyme/Lumizyme revenue is in structural decline: Q3 2026 sales fell 15.6% to just EUR 105 million as patients switch to Sanofi's own next-gen drug Nexviazyme, which generated EUR 211 million in the same quarter.
  • The FDA issued a Warning Letter to Sanofi's Waterford, Ireland manufacturing plant (Genzyme Ireland) on June 22, 2026, citing significant data integrity and quality control failures. This triggered supply shortages of both Myozyme and Nexviazyme reported in August 2026, creating regulatory and operational overhang.
  • As a 20-year-old approved biologic, Myozyme faces no binary regulatory catalyst. It is a mature, declining product within a EUR 50B+ diversified pharma giant, so its individual performance has negligible impact on Sanofi's share price.
● neutral
Impact
PhaseApproved
Time to marketAlready on market since 1997; generic widely available since 2012.

Plavix clopidogrel Updated Oct 31

What to watch

There are no hard, dated binary catalysts for Plavix in the next 12 months. The Texas Attorney General lawsuit (filed November 2025) is the most significant active legal overhang, but as a state-level fraud case with no trial date set, it is not a scheduled binary event. Investors should monitor any settlement or court ruling in the Texas case, but Plavix is too small a revenue contributor at Sanofi to drive a material share-price move from legal outcomes alone.

Bull case
  • Plavix remains a widely prescribed, standard-of-care antiplatelet therapy with durable demand, generating roughly $1 billion in annual revenue for Sanofi even in a genericized market.
  • Sanofi and BMS settled Hawaii's decade-long Plavix lawsuit for $700 million in May 2025, removing one major litigation overhang.
  • The drug's established safety profile and decades of real-world data support continued use in acute coronary syndrome and post-stroke patients worldwide.
Bear case
  • US patent exclusivity expired in 2012 and generic clopidogrel is available from at least 15 manufacturers at very low prices, severely limiting brand Plavix revenue in the US market.
  • Texas Attorney General Ken Paxton sued Sanofi and BMS in November 2025 for allegedly concealing that Plavix is less effective in certain ethnic populations; the case remains ongoing and could result in additional financial penalties.
  • Individual personal-injury lawsuits over bleeding and TTP (a rare blood disorder) continue to be filed in 2026, creating ongoing legal defense costs and reputational risk.
● neutral
Impact
PhaseApproved / marketed (IV since 2020, SC since 2026); additional Phase 2/3 studies completed or ongoing.
Time to marketAlready approved and marketed: IV formulation since March 2020; subcutaneous 'Sarclisa Escena' formulation approved July 9, 2026.

Sarclisa isatuximab Updated Aug 19

What to watch

Watch Sanofi's quarterly earnings disclosures for Sarclisa/Sarclisa Escena sales growth and launch uptake of the new subcutaneous on-body-injector form, plus any data presentations from completed isatuximab trials (a Phase 3 IV-vs-SC study finished primary completion Jan 30, 2026).

Bull case
  • FDA approved the subcutaneous formulation 'Sarclisa Escena' (isatuximab-irfc) on July 9, 2026 for all existing multiple myeloma indications, locally analyzed as the first anti-cancer treatment administered via an on-body injector, which can improve patient convenience and drive adoption.
  • The SC approval was supported by Phase 3 IRAKLIA data showing non-inferior efficacy with shorter administration time and fewer infusion reactions versus IV dosing (local 6-K analysis, Jul 2026).
  • Regulatory track record is intact: initial approval in March 2020, supplemental IV efficacy approval Oct 25, 2024, and the new SC dosage form in 2026, three FDA actions recorded in local data.
Bear case
  • No pending hard catalyst: the defining regulatory binaries for Sarclisa have already passed (SC approval July 9, 2026), and no upcoming FDA catalyst for SNY appears in local data for the next 180 days, so no dated event to trade on.
  • Low concentration: Sarclisa is one oncology asset at a ~$109B market-cap company (H1 2026 6-K market snapshot); the only recorded catalyst outcome for Sarclisa in local data was a modest +3.16% 1-day / +4.74% 5-day move around the 2020 approval.
  • Company-level headwinds temper sentiment: Sanofi's H1 2026 IFRS net income fell 66.3% (€1,031M impairment, mainly discontinued amlitelimab), and several tracked 13F managers neared or cut SNY positions in 2026-Q2.
● neutral
Impact
PhaseFiled/Under Review (EU); Phase 3 completed (US pending submission)
Time to marketEU approval (European Commission decision) expected within weeks (by late November 2026). US BLA submission planned for 2H 2026, with FDA review likely extending into 2027.

SP0087 purified vero rabies vaccine - serum free Updated Oct 31

What to watch

The next hard catalyst is the European Commission's final decision on VaxRabeo (SP0087), expected within weeks after the September 17 CHMP positive opinion. A positive decision would enable EU launch and potentially accelerate Sanofi's US BLA submission, which was planned for 2H 2026. For a company of Sanofi's scale, this is a pipeline maintenance event rather than a stock-moving binary.

Bull case
  • SP0087 (VaxRabeo) received a positive CHMP opinion on September 17, 2026, with the European Commission expected to grant marketing authorization across all EU member states, covering all age groups for both pre- and post-exposure prophylaxis.
  • Phase 3 trials demonstrated non-inferior immunogenicity versus licensed rabies vaccines, and the serum-free formulation represents a manufacturing advancement over Sanofi's current Verorab product.
  • Sanofi has signaled intent to submit a US BLA in 2H 2026, opening the world's largest vaccines market; the global rabies vaccine market is projected to grow at roughly 5% CAGR to $1.79 billion by 2031.
Bear case
  • As a next-generation version of Sanofi's own existing rabies vaccines (Verorab, Imovax), SP0087 may cannibalize the company's current rabies franchise rather than add entirely new revenue.
  • The global rabies vaccine market is modest at roughly $1.4 billion in 2026, limiting the commercial upside for any single new entrant.
  • Sanofi has not yet submitted a US BLA filing as of late October 2026 (planned for 2H 2026), meaning US approval is likely 12+ months away, delaying meaningful revenue.
● neutral
Impact
PhaseApproved
Time to marketAlready on the market since 1998 (US) and 1999 (FDA licensure). No new regulatory filing is pending.

Thymoglobulin anti-thymocyte globulin (rabbit) Updated Oct 31

What to watch

Thymoglobulin has no near-term binary catalysts. Watch for Sanofi's full-year 2026 results (expected late January 2027) for the annual sales figure, and monitor for any biosimilar development that could pressure the franchise. Neither event is likely to materially move SNY shares given the drug's tiny revenue contribution.

Bull case
  • Thymoglobulin sales are growing: Q3 2026 revenue was EUR 134 million, up 10.2% year-over-year, driven by Rest of World markets (+13.5%).
  • Full-year 2025 sales of EUR 124 million grew 6.4%, showing continued commercial momentum for a mature product.
  • Sanofi invested EUR 40 million to expand Thymoglobulin production capacity at its Lyon Gerland facility, signaling commitment to supply and potential growth.
Bear case
  • Thymoglobulin is a tiny fraction of Sanofi's portfolio: EUR 134 million in Q3 2026 vs. Sanofi's total Q3 sales of EUR 14.4 billion (less than 1% of revenue), so even strong growth has negligible impact on Sanofi's stock.
  • As a biologic (rabbit-derived antibody), Thymoglobulin faces eventual biosimilar competition, though no biosimilar is currently approved.
  • The product is mature (nearly 30 years on the market) with limited expansion opportunity beyond its established kidney transplant indication.
● neutral
Impact
PhasePhase 2 (completed per local data)
Time to marketUnknown — local data shows only completed Phase 2 studies (ITP and atopic dermatitis); no FDA filing or approval records are present locally and external verification was unavailable, so time to potential approval/commercialization cannot be estimated.

Wayrilz rilzabrutinib Updated Aug 2

What to watch

Watch Sanofi's 6-K filings and corporate updates for any FDA/EMA filing announcement or late-stage readout for rilzabrutinib (ITP and atopic-dermatitis Phase 2 studies are complete); with none verifiable, there is no dated binary to trade today.

Bull case
  • Developer verified: ticker SNY resolves to Sanofi (CIK 0001121404, ADR), a large diversified pharma with the capital and commercial infrastructure to develop and launch the drug.
  • Internal ClinicalTrials.gov records show two Sanofi/Principia rilzabrutinib Phase 2 trials (ITP, atopic dermatitis) COMPLETED with results posted, indicating the program advanced beyond early stage.
  • Sanofi ADR analyst snapshot is constructive: consensus (29 ratings, period 2026-07-01) has 16 buy/strong-buy vs 13 hold/sell, and the 9-analyst price-target snapshot shows mean $54.61 vs ~$43.08 close, roughly 26.5% implied upside per the local data.
Bear case
  • No FDA action records (approval, CRL, or safety labeling) and no catalyst/outcome records for rilzabrutinib exist in the local datasets, meaning regulatory status and any upcoming PDUFA/readout are unknown, there is no dated binary to trade.
  • Analyst sentiment cooled through late 2025: local records show downgrades by UBS (Buy→Neutral, Jan 2026), Barclays (Overweight→Equal-Weight, Jan 2026), Guggenheim (Buy→Neutral, Dec 2025) and JP Morgan (Overweight→Neutral, Dec 2025).
  • BTK inhibitors are a crowded, established class (ibrutinib, acalabrutinib, zanubrutinib, pirtobrutinib family), so any new entrant faces strong competition and pricing pressure.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed (FDA approval August 2022, EMA June 2022, Japan March 2022).

Xenpozyme olipudase alfa Updated Oct 31

What to watch

Xenpozyme is already approved and commercializing with no pending regulatory decisions or pivotal readouts. The next catalyst to watch would be Sanofi's full-year 2026 earnings (expected early February 2027) for Xenpozyme's annual sales growth trajectory. For a diversified giant like Sanofi, Xenpozyme's performance is unlikely to be a material stock-moving event on its own.

Bull case
  • Xenpozyme is the first and only approved treatment for ASMD, giving it a monopoly position in an ultra-rare disease with no direct competition.
  • Sales grew 50% year-over-year to EUR 38 million in 2024, driven by increased patient identification and geographic expansion.
  • Patent protection extends to approximately March 2035, providing a long exclusivity runway.
Bear case
  • ASMD affects fewer than 120 patients in the U.S., capping the addressable market and revenue potential at a small fraction of Sanofi's total sales.
  • Xenpozyme is a tiny component of Sanofi's EUR 46.7 billion+ annual revenue, so even strong growth has negligible impact on Sanofi's stock price.
  • The drug carries a Boxed Warning for anaphylaxis risk, and infusion-related reactions are common.
● neutral
Impact
PhasePhase 1/2 (listed as Phase 2 in pipeline databases)
Time to marketYears away, if ever. The drug is in Phase 1/2 testing. Even after the ongoing study reads out, additional Phase 2b/3 trials and regulatory review would be needed before any potential approval. Pandemic vaccines also face uncertain demand outside of outbreak scenarios.

SP0289 pandemic influenza H5 HA mRNA vaccine Updated Oct 31

What to watch

The next milestone to watch is the estimated primary completion of the Phase 1/2 SD2 trial (NCT06907511) around December 2026, with topline immunogenicity and safety data likely following in early 2027. Given Sanofi's size and diversification, this readout is unlikely to be a material stock-moving event for SNY. Investors should view SP0289 as a minor pipeline filler, not a value driver.

Bull case
  • Sanofi management described preliminary Phase 1/2 data as 'very encouraging,' suggesting the vaccine generates a meaningful immune response against H5N1.
  • The ongoing H5N1 bird flu panzootic (spreading in mammals since 2020) creates real pandemic preparedness demand, and governments may stockpile effective vaccines.
  • Sanofi is a global vaccines leader with established manufacturing and distribution infrastructure, giving it advantages in bringing a pandemic vaccine to market if needed.
Bear case
  • The drug is in very early (Phase 1/2) development; most early-stage vaccine candidates fail to reach approval.
  • Sanofi already scrapped its seasonal mRNA flu vaccine (SP0237) in early 2026, raising questions about the company's mRNA platform viability.
  • Pandemic vaccine demand is inherently episodic and government-dependent; without an active H5N1 outbreak in humans, commercial opportunity is limited.
● neutral
ImpactNot rated
PhaseNot stated
Time to marketNot stated

MenQuadfi Updated Oct 31

What to watch

MenQuadfi is already approved and commercialized in both the US and EU. The next catalysts would be country-level reimbursement decisions and ACIP schedule updates following the infant label expansions, but these are gradual commercial events rather than binary stock-moving catalysts. Watch for Sanofi's quarterly vaccine segment sales for evidence of MenQuadfi market share gains against GSK's Menveo and Nimenrix.

Bull case
  • [""MenQuadfi is the first quadrivalent meningococcal conjugate vaccine approved for infants as young as 6 weeks of age in both the US (May 2025) and the EU (August 2025), expanding the addressable pediatric market significantly.", "The meningococcal vaccine market is growing at a 7-9% CAGR, with the meningitis vaccine market projected to reach USD 4.65B in 2026 growing to USD 6.61B by 2026, per Mordor Intelligence.", "MenQuadfi has WHO prequalification from the WHO, enabling procurement by UN agencies and UNICEF, opening global health organization procurement, enabling procurement by UN agencies.", "Sanofi has a strong pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with 24 in Phase 3 or submitted for approval, per its pipeline of 61 clinical-stage projects with
Bear case
  • MenQuadfi competes in a concentrated market against GSK's Menveo and Nimenrix and Pfizer's Trumenba (serogroup B), limiting pricing power and share gains.
  • Sanofi's overall vaccine segment faced headwinds in 2025-2026, with declining immunization rates in the US and a 'soft' start to fall immunizations pressuring sales.
  • MenQuadfi is one of many products in Sanofi's massive portfolio (~EUR 47B revenue in 2025); even strong MenQuadfi performance has limited impact on the overall stock.

Other drugs in filings and trials

no drug report yet
  • MERILOG Last: Approval · Feb 14, 2025
  • FEXINIDAZOLE Last: Approval · Jul 16, 2021
  • ADMELOG Last: Approval · Dec 11, 2017
  • KEVZARA Last: Approval · May 22, 2017
  • XYZAL ALLERGY 24HR Last: Approval · Jan 31, 2017
  • SOLIQUA 100/33 Last: Approval · Nov 21, 2016
  • ADLYXIN Last: Approval · Jul 27, 2016
  • TOUJEO SOLOSTAR Last: Approval · Feb 25, 2015
  • AUBAGIO Last: Approval · Sep 12, 2012
  • ZALTRAP Last: Approval · Aug 3, 2012
  • Amlitelimab 4 trials
  • balinatunfib 1 trial
  • Dupilumab 3 trials
  • Itepekimab (SAR440340) 1 trial
  • Lunsekimig 3 trials
  • NVX-CoV2705 1 trial
  • RSVt Vaccine 1 trial
  • SAR441566 2 trials
  • SQIN-Furosemide 1 trial
  • Yellow fever vaccine (live) 1 trial

Past FDA events & how the stock moved

11 events
DateDrugEvent1 day5 days
Feb 14, 2025MERILOGApproval−0.1%−0.4%
Jul 16, 2021FEXINIDAZOLEApproval−0.7%+0.7%
Mar 2, 2020SarclisaApproval+3.2%−2.2%
Dec 11, 2017ADMELOGApproval+1.7%+0.6%
May 22, 2017KEVZARAApproval−0.5%−0.5%
Jan 31, 2017XYZAL ALLERGY 24HRApproval+2.2%+0.6%
Nov 21, 2016SOLIQUA 100/33Approval−0.4%+1.0%
Jul 27, 2016ADLYXINApproval+1.2%−2.8%
Feb 25, 2015TOUJEO SOLOSTARApproval−3.0%−4.1%
Sep 12, 2012AUBAGIOApproval+1.3%+2.4%
Aug 3, 2012ZALTRAPApproval+4.0%+4.0%

Clinical trials

40 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
Investigational hMPV/RSV vaccineStudy of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and OlderPhase 2Active not recruiting1,530Jan 18, 2027
ALTUVIIIOLong-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia APhase 3Active not recruiting261Jan 15, 2027
SP0289Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and OlderPhase 2Active not recruiting720Dec 1, 2026
PCV21Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and AdolescentsPhase 3Active not recruiting1,268Dec 1, 2026
balinatunfibA Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)Phase 2Terminated7Sep 29, 2026
AmlitelimabLong-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical StudyPhase 2Terminated335Sep 22, 2026
QfitliaLong-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IXPhase 3Completed281Sep 14, 2026
Itepekimab (SAR440340)A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPDPhase 3Completed669Sep 10, 2026
SAR441566A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative ColitisPhase 2Terminated170Aug 6, 2026
AmlitelimabA Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac DiseasePhase 2Active not recruiting229Aug 5, 2026
QfitliaFitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or BPhase 3Completed32Aug 4, 2026
SAR441566A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.Phase 2Terminated105Jul 30, 2026
SAR441344 IVEfficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus ErythematosusPhase 2Active not recruiting109Jul 10, 2026
AmlitelimabA Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic DermatitisPhase 3Active not recruiting1,541Jun 29, 2026
DupilumabA Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)Phase 3Completed138Jun 8, 2026
DupilumabA Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)Phase 3Completed142Jun 8, 2026
Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and OlderPhase 2Completed1,162May 22, 2026
AK112A Study of AK112 With or Without AK117 in Metastatic Colorectal CancerPhase 2Active not recruiting254May 15, 2026
DupilumabA Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))Phase 2Active not recruiting68May 15, 2026
venglustatA Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry DiseasePhase 3Active not recruiting104May 15, 2026
MenACYW conjugate vaccineImmunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in ChinaPhase 3Completed1,602May 1, 2026
IIV-HDStudy of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and OlderPhase 2Completed980Apr 16, 2026
RIV (recombinant influenza vaccine)Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and OlderPhase 2Completed980Apr 3, 2026
Itepekimab (SAR440340)A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal PolypsPhase 2Completed66Mar 31, 2026
SP0289Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and OlderPhase 2Completed276Mar 24, 2026
—Actual Use Trial of Tadalafil 5 mgPhase 3Completed2,212Mar 2, 2026
SQIN-FurosemideUse of a Novel SUBCUTaneous Preparation of Furosemide to Facilitate Early Supported Discharge of Patients With Heart FailurePhase 2Completed172Mar 1, 2026
RSV/hMPV vaccine candidate Dose LStudy of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine CandidatePhase 2Completed646Feb 27, 2026
LunsekimigDose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe AsthmaPhase 2Completed685Feb 23, 2026
LunsekimigA Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic DermatitisPhase 2Completed150Feb 12, 2026
SarclisaLenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple MyelomaPhase 3Completed514Jan 30, 2026
lunsekimigA Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal PolypsPhase 2Completed79Jan 29, 2026
Yellow fever vaccine (live)Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in AdultsPhase 3Completed640Jan 20, 2026
InsulinEfficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 DiabetesPhase 2Completed114Jan 20, 2026
NVX-CoV2705Safety and Immunogenicity of NVX-CoV2705Phase 3Completed676Jan 12, 2026
Eliglustat GZ385660Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3Phase 3Completed57Dec 26, 2025
Yellow fever vaccine (live)Phase 3 Single Arm, Open Study on vYF in AdultsPhase 3Completed254Dec 25, 2025
NicodermAdaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine RespondersPhase 3Completed150Dec 9, 2025
RSVt VaccineEfficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and ToddlersPhase 3Terminated6,300Dec 4, 2025
AmlitelimabA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)Phase 3Completed589Nov 25, 2025